BPC-157

Overall Benefits of BPC-157

• Accelerates wound healing [1-12]
• Accelerates healing of soft tissue injuries [13-28]
• Improves bone and joint health [29-32]
• Improves digestive health [33-45]
• Normalizes blood pressure [46-49]
• Corrects potassium imbalance [50-55]
• Corrects calcium imbalance [56]
• Corrects magnesium imbalance [57]
• Strengthens the immune system [58-63]
• Protects against NSAID toxicity and related adverse side effects [64-68]
• Reverses alcohol intoxication [69-72]
• Improves mood and behavior [73-77]
• Improves cognitive health [78-82]
• Exerts anti-cancer properties [83-86]

What is BPC-157?

BPC-157, also known as Body Protecting Compound, is a 15-amino acid long peptide. A peptide is simply a compound consisting of two or more amino acids. Your body already produces BPC-157 in very small amounts, where it serves to signal for certain body processes to happen and protect the digestive system. Researchers believe that if you get the super concentrated version of BPC-157 into your system, it has an extremely high level of regenerative effects.

How BPC-157 works?

BPC-157 works by stimulating the formation of new blood vessels. This process is called angiogenesis and is important in promoting healing and faster cell regeneration. Angiogenesis is an integral part of the wound healing process and the organization of the blood vessel network.

Chemical Structure of BPC-157

Research on BPC-157

Accelerates Wound Healing

Numerous studies show that BPC-157 may help accelerate the wound healing process through the following important mechanisms:

1. In mice with burn injuries, BPC-157 significantly improved collagen fiber formation and decreased the number of inflammatory cells. [1-4]
2. In wounded rats, BPC-157 administration enhanced the formation of granulation tissues (new tissues that form on an ulcer or the healing surface of a wound) and new blood vessels. [5-6]
3. A study found that BPC-157 enhanced wound healing in a model of alkali burn-induced skin injury. [7]
4. In rats with intestinal lesions, BPC-157 administration significantly reduced damage to blood vessels and occlusion. [8-9]
5. In rats with celecoxib-induced gastrointestinal, liver, and brain lesions, BPC-157 reversed the damaging effect of the drug. [10]
6. In broiler chicks with severe damage to the tissues of the heart, liver, and spleen, BPC-157 administration at 10 micrograms/kg reduced organ damage. [11]
7. In honeybees with severe damage to midgut wall layers, supplementation with sugar syrup containing BPC-157 decreased damage to the outer muscular coat. [12]

Accelerates Healing of Soft Tissue Injuries

Soft tissue injuries refer to damage to the muscles, tendons, and ligaments. They can be partial or complete tears and may require surgical repair. Interestingly, studies show that BPC-157 may help accelerate healing of soft tissue injuries:

1. In rats with Achilles tendon injury, BPC-157 significantly improved healing, thereby eliminating the need for surgical repair. [13-15]
2. BPC-157 promoted tendon outgrowth, cell survival, and cell migration in injured soft tissues of rats. [16-18]
3. In rats with muscle crush injury, BPC-157 induced faster muscle healing and full function restoration. [19-21]
4. In rat tendon cells, pretreatment with BPC-157 showed outcome close to noninjured ligament as evidenced by faster granulation tissue formation, better organization of collagen, and reduced inflammatory cells. [22]
5. In rats that had surgical operation of the colon, BPC-157 treatment accelerated the healing time. [23]
6. In rats with eye injuries, administration of BPC-157 eye drops successfully closed perforating corneal incisions. [24-25]
7. In rats with injury to the sciatic nerve (nerve in the spinal cord), BPC-157 administration reversed death of nerve cells and cyst formation and protected against damage to nerve structures. [26]
8. A study also found that BPC-157 has the capacity to protect against cancer cachexia, a condition characterized by progressive loss of muscle and fat. [27]
9. In rats with vessel injury, BPC-157 administration counteracted direct vein injury, blood clots, and prolonged bleeding. [28]

Improves Bone and Joint Health

BPC-157 plays a crucial role in maintaining bone and joint health. Studies show that BPC-157 exerts this beneficial effect through the following:

1. In rabbits, BPC-157 significantly improved the healing of segmental bone defects by increasing bone density. [29]
2. In rats, BPC-157 administration counteracted knee osteoarthritis and reduced cartilage lesions, resulting in improved leg length and mobility. [30-32]

Improves Digestive Health

BPC-157 may also help improve digestive health through the following:

1. In rats, BPC-157 prevented the development of gastric ulcers by protecting the layers of the stomach against the direct cellular damaging effect of ethanol. [33-34]
2. BPC-157 fully interacted with the dopamine system (group of nerve cells in the midbrain) of rats to prevent mechanisms involved in ulcer formation. [35]
3. Continuous administration of BPC-157 in rats with chronic gastric ulcers accelerated rebuilding of stomach tissues and formation of granulation tissues. [36]
4. BPC-157 administration in rats reduced gastrointestinal tract lesions. [37-40]
5. In rats with inflammatory bowel disease, BPC-157 administration resulted in faster healing of damaged colon. [41-45]

Normalizes Blood Pressure

Studies show that BPC-157 can help normalize blood pressure through the following mechanisms:

1. In rats with abnormally low blood pressure, BPC-157 exerted hypertensive effects by increasing blood pressure near the normal range. [46-47]
2. In rats with high blood pressure, BPC-157 decreased blood pressure by causing blood vessels to dilate. [48-49]

Corrects Potassium Imbalance

Normal blood levels of potassium are crucial for optimum heart health. Abnormally low or high potassium levels can both lead to heart failure. Studies show that BPC-157 can help protect against heart failure caused by potassium imbalance:

1. In rats with hyperkalemia (potassium overdose), BPC-157 therapy protected against heart failure by completely restoring the normal heart rhythm and electrical activities of the heart. [50-53]
2. In rats with hypokalemia (potassium deficiency), BPC-157 therapy protected against heart failure by counteracting abnormal heart rhythm. [54-55]

Corrects Calcium Imbalance

Hypercalcemia (excessive calcium levels) negatively affects almost every organ system in the body. Evidence suggests that BPC-157 can counteract life-threatening conditions associated with high calcium levels:

1. In rats, BPC-157 administration protected against organ failure induced by hypercalcemia via reduction of calcium deposits. [56]

Corrects Magnesium Imbalance

High levels of magnesium in the blood (hypermagnesemia) can lead to life-threatening conditions including heart problems, breathing difficulties, and coma. Evidence found that BPC-157 can help reverse this electrolyte imbalance:

1. In rats, BPC-157 administration counteracted the initial event leading to hypermagnesemia and the life-threatening effects of magnesium overdose. [57]

Strengthens the Immune System

BPC-157 can help boost the immune system and protect against infection caused by virus, bacteria and other disease-causing microorganisms through the following important mechanisms:

1. BPC-157 has been shown to have anti-inflammatory and regenerative effects on multiple target tissues and organs of rats. [58]
2. In rats, BPC-157 increased the production of growth factors that fight infections such as vascular endothelial growth factor (VEGF), ultimately strengthening the immune system. [59-62]
3. A cell study found that BPC-157 has the potential to reduce intestinal inflammation through its antioxidant properties. [63]

Protects against NSAID Toxicity and Related Adverse Side Effects

Studies show that BPC-157 effectively reduces the adverse side effects and toxicity of non-steroidal anti-inflammatory (NSAIDs) medications through the following protective mechanisms:

1. In rats, BPC-157 effectively counteracted several established side-effects of NSAIDs use such as lesions in the gastrointestinal tract, liver and brain, prolonged bleeding, and low blood platelet count (thrombocytopenia). [64]
2. In rats, oral supplementation and injection of BPC-157 effectively treated severe gastric, intestinal and liver lesions, liver problems, prolonged sedation/unconsciousness, brain abnormalities, and organ failure induced by NSAIDs. [65-68]

Reverses Alcohol Intoxication

BPC-157 can help reverse the adverse effects of acute and chronic alcohol intoxication. Studies show that BPC-157 exerts this effect through the following:

1. In mice, BPC-157 rapidly opposed the strongest disturbance presentations in acute alcohol intoxication such as loss of muscle reflex, no reaction to external stimuli, and low body temperature, as well as symptoms of alcohol withdrawal such as prominent seizures. [69]
2. BPC-157 protected against both acute and chronic alcohol-induced lesions in the stomach, esophagus, and liver of mice. [70-72]

Improves Mood and Behavior

Studies show that BPC-157 may help improve mood and behavior:

1. In rats, BPC-157 administration reduced immobility time in a forced swimming test (used for evaluation of antidepressant drugs), which is indicative of a potent antidepressant effect. [73]
2. In rats, BPC-157 administration produced an anti-anxiety effect. [74]
3. In rats chronically exposed to amphetamine, BPC-157 decreased behavioral disturbances caused by the drug. [75]
4. In rats with serotonin syndrome, a condition characterized by high body temperature, agitation, tremor, increased reflexes, sweating, dilated pupils, and digestive problems, BPC-157 administration counteracted behavioral disturbances and other associated symptoms. [76]
5. In mice chronically exposed to diazepam, BPC-157 significantly decreased drug tolerance, physical dependence, and withdrawal symptoms. [77]

Improves Cognitive Health

An overwhelming body of research supports the benefits of BPC-157 on the brain:

1. In rats with brain damage similar to Parkinson’s disease (PD), administration of BPC-157 appears to mitigate some of the damage. [78]
2. In rodents with multiple sclerosis (MS), a chronic disease affecting the brain and spinal cord, oral BPC-157 administration decreased brain damage and clinical abnormalities. [79-80]
3. In rats with traumatic brain injury, BPC-157 administration is associated with a reduction of unconsciousness and lower prevalence of deaths. [81]
4. In rats, BPC-157 counteracted ischemic/reperfusion injuries (tissue damage caused when blood supply returns after a period of insufficient blood circulation in the brain), resulting in improved memory, orientation, and motor capabilities. [82]

Exerts Anti-Cancer Properties

Therapeutic peptides such as BPC-157 are known to possess potent anti-cancer activity. Most animal studies assessing the therapeutic benefits of BPC-157 has shown that this therapeutic peptide helps fight cancer by:

1. Inducing programmed cell death (apoptosis) of cancer cells [83-85]
2. Assembling and forming pores that can disrupt the structures of cancer cells [86]

Associated Side Effects of BPC-157

BPC-157 side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on BPC-157. However, the issue wasn’t’ confirmed to be caused by the treatment and could have been a coincidence and not related to the use of BPC-157. Despite this, it was listed as a side effect associated with BPC-157 even these associated side effects are very uncommon.
Side effects associated with BPC-157 may include the following:

• Changes in blood pressure
• Changes in heart rhythm
• Dizziness
• Fatigue
• Hot flashes
• Nausea and vomiting

References

1. Mikus D, Sikiric P, Seiwerth S. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns : journal of the International Society for Burn Injuries. 2001; 27(8):817-27. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11718984.
2. Bilic M., Bumber Z., Blagaic A.B., Batelja L., Seiwerth S., Sikiric P. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice. Burns. 2005;31(3):310–315. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15774286.
3. Sikiric P., Seiwerth S., Mise S., Staresinic M., Bedekovic V., Zarkovic N., Borovic S., Gjurasin M., Boban-Blagaic A., Batelja L., Rucman R., Anic T. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns. 2003;29(4):323–334. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12781609.
4. Mikus D, Sikiric P, Seiwerth S. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns : journal of the International Society for Burn Injuries. 2001; 27(8):817-27. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11718984.
5. Seiwerth S, Sikiric P, Grabarevic Z. BPC 157’s effect on healing. Journal of physiology, Paris. ; 91(3-5):173-8. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9403790.
6. Seveljević-Jaran D, Cuzić S, Dominis-Kramarić M. Accelerated healing of excisional skin wounds by PL 14736 in alloxan-hyperglycemic rats. Skin pharmacology and physiology. 2006; 19(5):266-74. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16785777.
7. Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485–2499. doi: 10.2147/DDDT.S82030.
8. Drmic D, Samara M, Vidovic T, et al. Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine. World J Gastroenterol. 2018;24(48):5462-5476. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30622376.
9. Amic F, Drmic D, Bilic Z, et al. Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine. World J Gastroenterol. 2018;24(47):5366-5378. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30598581.
10. Drmic D, Kolenc D, Ilic S, et al. Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. World J Gastroenterol. 2017;23(29):5304-5312. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29510201.
11. Grabarevic Z, Tisljar M, Artukovic B, et al. The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks. J Physiol Paris. 1997;91(3-5):139-49. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9403788.
12. TlakGajger I, Ribarić J, SmodišŠkerl M, Vlainić J, Sikirić P. Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions. J Vet PharmacolTher. 2018;41(4):614-621. doi:10.1111/jvp.12509.
13. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of orthopaedicresearch : official publication of the Orthopaedic Research Society. 2006; 24(5):982-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16583442.
14. Staresinic M., Sebecic B., Patrlj L., Jadrijevic S., Suknaic S., Perovic D., Aralica G., Zarkovic N., Borovic S., Srdjak M., et al. Gastric pentadecapeptide BPC 157 accelerated healing of transected rat Achilles tendon and in vitro stimulates tenocytes growth. J. Orhtop. Res. 2003;21:976–983. doi: 10.1016/S0736-0266(03)00110-4.
15. Molloy T.J., Wang Y., Horner A., Skerry T.M., Murrell G.A. Microarray analysis of healing rat Achilles tendon: Evidence for glutamate signaling mechanisms and embryonic gene expression in healing tendon tissue. J. Orthop. Res. 2006;24:842–855. doi: 10.1002/jor.20093.
16. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985). 2011; 110(3):774-80. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21030672.
17. Staresinic M, Sebecic B, Patrlj L. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2003; 21(6):976-83. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/14554208.
18. Gjurasin M, Miklic P, Zupancic B. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regulatory peptides. 2010; 160(1-3):33-41. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19903499.
19. Pevec D, Novinscak T, Brcic L. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical science monitor : international medical journal of experimental and clinical research. 2010; 16(3):BR81-88. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20190676.
20. Novinscak T, Brcic L, Staresinic M. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surgery today. 2008; 38(8):716-25. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18668315.
21. Staresinic M, Petrovic I, Novinscak T. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2006; 24(5):1109-17. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16609979.
22. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. Published 2014 Nov 19. doi:10.3390/molecules191119066.
23. Zoricic I., Sikiric P., Seiwerth S. Pentadecapeptide BPC-157 beneficially influences the healing of colon-colon anastamoses in rats. In: Mozsik G., Nagy L., Par A., Rainsford K., editors. Cell Injury and Protection in the Gastrointestinal Tract. From Basic Science to Clinical Perspectives. Kluwer Academic Publishers; Dodrecht, The Netherlands: 1997. pp. 249–258.
24. Konjevoda P., Nasic M., Curkovic T. Effects of BPC-157 on the healing of corneal lesions. In: Ohno S., Aoki K., Usui M., editors. Uveitis Today. Elsevier; Amsterdam, The Netherlands: 1998. pp. 311–314.
25. Masnec S, Kokot A, Zlatar M, et al. Perforating corneal injury in rat and pentadecapeptide BPC 157. Exp Eye Res. 2015;136:9-15.
26. Perovic D, Kolenc D, Bilic V, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res. 2019;14(1):199. Published 2019 Jul 2. doi:10.1186/s13018-019-1242-6.
27. Kang EA, Han YM, An JM, Park YJ, Sikiric P, Kim DH, et al. BPC157 as potential agent rescuing from cancer cachexia. Curr Pharm Des. 2018;24(18):1947–1956. doi: 10.2174/1381612824666180614082950.
28. Vukojević J, Siroglavić M, Kašnik K, et al. Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157. VasculPharmacol. 2018;106:54-66. doi:10.1016/j.vph.2018.02.010.
29. Sebecić B, Nikolić V, Sikirić P. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone. 1999; 24(3):195-202. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10071911.
30. Retrieved from http://www.fasebj.org/content/28/1_Supplement/844.11?related-urls=yes&legid=fasebj;28/1_Supplement/844.11.
31. Retrieved from http://www.fasebj.org/content/27/1_Supplement/888.9.short.
32. Retrieved from https://www.sciencedirect.com/science/article/pii/S0928425797894740.
33. Bódis B, Karádi O, Németh P, Dohoczky C, Kolega M, Mózsik G. Evidence for direct cellular protective effect of PL-10 substances (synthesized parts of body protection compound, BPC) and their specificity to gastric mucosal cells. Life sciences. 1997; 61(16):PL 243-8. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9353174.
34. Prkacin I., Aralica G., Perovic D., Separovic J., Gjurasin M., Lovric-Bencic M., Stancic-Rokotov D., Ziger T., Anic T., Sikiric P., et al. Chronic cytoprotection: Pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J. Physiol. Paris. 2001;95:295–301. doi: 10.1016/S0928-4257(01)00041-9.
35. Jelovac N, Sikiric P, Rucman R. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. European journal of pharmacology. 1999; 379(1):19-31. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10499368.
36. Xue XC, Wu YJ, Gao MT. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World journal of gastroenterology. 2004; 10(7):1032-6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15052688.
37. Stancic-Rokotov D, Slobodnjak Z, Aralica J. Lung lesions and anti-ulcer agents beneficial effect: anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rats. Journal of physiology, Paris. ; 95(1-6):303-8. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11595454.
38. Sikiric P, Seiwerth S, Grabarevic Z. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life sciences. 1994; 54(5):PL63-8. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/7904712.
39. Djakovic Z, Djakovic I, Cesarec V, et al. Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME. World Journal of Gastroenterology. 2016;22(41):9127-9140. doi:10.3748/wjg.v22.i41.9127. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107594/.
40. Klicek R., Sever M., Radic B., Drmic D., Kocman I., Zoricic I., Vuksic T., Ivica M., Barisic I., Ilic S., et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: Role of the nitric oxide-system. J. Pharmacol. Sci. 2008;108:7–17. doi: 10.1254/jphs.FP0072161.
41. Sikiric P., Petek M., Rucman R., Seiwerth S., Grabarević Z., Rotkvić I., Jagić V., Turković B., Mildner B., Duvnjak M., et al. The significance of the gastroprotective effect of body protection compound (BPC): Modulation by different procedures. Acta Physiol. Hung. 1992;80:89–98.
42. Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972–1989. doi: 10.2174/1381612824666180712110447.
43. Sikiric P, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Curr Pharm Des. 2018;24(18):1990–2001. doi: 10.2174/1381612824666180608101119.
44. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012;19(1):126–132. doi: 10.2174/092986712803414015.
45. Duzel A, Vlainic J, Antunovic M, Malekinusic D, Vrdoljak B, Samara M, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World J Gastroenterol. 2017;23(48):8465–8488. doi: 10.3748/wjg.v23.i48.8465.
46. Sikirić P, Seiwerth S, Grabarević Z. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European journal of pharmacology. 1997; 332(1):23-33. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9298922.
47. Sikiric P, Seiwerth S, Rucman R. Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution? Current pharmaceutical design. 2017; 23(27):4012-4028. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28228068.
48. Sikiric P, Seiwerth S, Rucman R. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current pharmaceutical design. 2014; 20(7):1126-35. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23755725.
49. Prkacin I, Separovic J, Aralicia G. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. Journal of physiology, Paris. ; 95(1-6):315-24. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11595456.
50. Barisic I, Balenovic D, Klicek R. Mortal hyperkalemia disturbances in rats are NO-system related. The life-saving effect of pentadecapeptide BPC 157. Regulatory peptides. 2013; 181:50-66. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23327997.
51. Stambolija V, Stambolija TP, Holjevac JK. BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias. European journal of pharmacology. 2016; 781:83-91. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27060013.
52. Available from https://www.bib.irb.hr/467793.
53. Zivanovic-Posilovic G, Balenovic D, Barisic I. Stable gastric pentadecapeptide BPC 157 and bupivacaine. European journal of pharmacology. 2016; 793:56-65. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27815173.
54. Strinic D, Belosic Halle Z, Luetic K. BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats. Life sciences. 2017; 186:66-79. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28797793.
55. Retrieved from https://www.omicsonline.org/mortal-furosemide-hypokalemia-disturbances-in-rats-no-system-related-shorten-survival-by-l-name.-therapy-benefit-with-bpc-157-peptide-morethan-with-l-arginine-2155-9880.1000201.php?aid=6879.
56. Ilic S, Brcic I, Mester M. Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2009; 60 Suppl 7:107-14. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20388953.
57. Medvidovic-Grubisic M, Stambolija V, Kolenc D. Hypermagnesemia disturbances in rats, NO-related: pentadecapeptide BPC 157 abrogates, L-NAME and L-arginine worsen. Inflammopharmacology. 2017; 25(4):439-449. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28210905.
58. Keremi B, Lohinai Z, Komora P. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2009; 60 Suppl 7:115-22. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20388954.
59. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2009; 60 Suppl 7:191-6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20388964.
60. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug testing and analysis. 2017; 9(10):1490-1498. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28035768.
61. Sikiric P, Seiwerth S, Rucman R. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current neuropharmacology. 2016; 14(8):857-865. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27138887.
62. Hsieh MJ, Liu HT, Wang CN. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of molecular medicine (Berlin, Germany). 2017; 95(3):323-333. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27847966.
63. Škrlec K, Ručman R, Jarc E, et al. Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities. Appl Microbiol Biotechnol. 2018;102(23):10103-10117. doi:10.1007/s00253-018-9333-6.
64. Sikiric P, Seiwerth S, Rucman R. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current pharmaceutical design. 2013; 19(1):76-83. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22950504.
65. Ilic S, Drmic D, Franjic S. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life sciences. 2011; 88(11-12):535-42. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21295044.
66. Vitaic S, Stupnisek M, Drmic D. Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatricpentadecapeptide BPC 157 in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2017; 68(2):265-272. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28614776.
67. Sikiric P, Seiwerth S, Rucman R. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current pharmaceutical design. 2011; 17(16):1612-32. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21548867.
68. Ilic S, Drmic D, Zarkovic K. Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats. European journal of pharmacology. 2011; 667(1-3):322-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21645505.
69. Boban-Blagaic A, Blagaic V, Romic Z. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. The effect of N(G)-nitro-L-arginine methyl ester and L-arginine. Medical science monitor : international medical journal of experimental and clinical research. 2006; 12(1):BR36-45. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16369461.
70. Blagaic AB, Blagaic V, Romic Z, Sikiric P. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. European journal of pharmacology. 2004; 499(3):285-90. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15381050.
71. Sikiric P, Seiwerth S, Brcic L. Revised Robert’s cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator. Current pharmaceutical design. 2010; 16(10):1224-34. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20166993.
72. Sikiric P, Seiwerth S, Brcic L. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006; 14(5-6):214-21. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/17186181.
73. Sikiric P, Separovic J, Buljat G. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt’s test and chronic unpredictable stress in rats. A comparison with antidepressants. Journal of physiology, Paris. ; 94(2):99-104. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10791689.
74. Sikiric P, Jelovac N, Jelovac-Gjeldum A. Anxiolytic effect of BPC-157, a gastric pentadecapeptide: shock probe/burying test and light/dark test. ActapharmacologicaSinica. 2001; 22(3):225-30. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11742568.
75. Sikiric P, Jelovac N, Jelovac-Gjeldum A. Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances. ActapharmacologicaSinica. 2002; 23(5):412-22. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11978191.
76. BobanBlagaic A, Blagaic V, Mirt M. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. European journal of pharmacology. 2005; 512(2-3):173-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15840402.
77. Jelovac N, Sikiric P, Rucman R. The effect of a novel pentadecapeptide BPC 157 on development of tolerance and physical dependence following repeated administration of diazepam. The Chinese journal of physiology. 1999; 42(3):171-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10707891.
78. Sikiric P, Marovic A, Matoz W. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson’s disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine. Journal of physiology, Paris. 1999; 93(6):505-12. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10672997.
79. Klicek R, Kolenc D, Suran J. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2013; 64(5):597-612. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24304574.
80. Torkildsen O, Brunborg LA, Myhr KM, Bø L. The cuprizone model for demyelination. ActaneurologicaScandinavica. Supplementum. 2008; 188:72-6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18439226.
81. Tudor M, Jandric I, Marovic A. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regulatory peptides. 2010; 160(1-3):26-32. Available from https://www.ncbi.nlm.nih.gov/pubmed/19931318.
82. Retrieved from http://www.fasebj.org/content/30/1_Supplement/706.5.short.
83. Yu-Feng Xiao, Meng-MengJie, Bo-Sheng Li, et al., “Peptide-Based Treatment: A Promising Cancer Therapy,” Journal of Immunology Research, vol. 2015, Article ID 761820, 13 pages, 2015. doi:10.1155/2015/761820. Retrieved from https://www.hindawi.com/journals/jir/2015/761820/cta/.
84. Cerezo D, Peña MJ, Mijares M, Martínez G, Blanca I, De Sanctis JB. Peptide vaccines for cancer therapy. Recent patents on inflammation & allergy drug discovery. 2015; 9(1):38-45. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25642777.
85. Kumai T, Kobayashi H, Harabuchi Y, Celis E. Peptide vaccines in cancer-old concept revisited. Current opinion in immunology. 2017; 45:1-7. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27940327.
86. Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR. The Use of Therapeutic Peptides to Target and to Kill Cancer Cells. Current medicinal chemistry. 2012;19(22):3794-3804. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537071/.